IMMUNIC, INC. Files Q1 2025 10-Q Report

Ticker: IMUX · Form: 10-Q · Filed: May 15, 2025 · CIK: 1280776

Immunic, INC. 10-Q Filing Summary
FieldDetail
CompanyImmunic, INC. (IMUX)
Form Type10-Q
Filed DateMay 15, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-Q, quarterly-report, pharmaceuticals

TL;DR

IMMUNIC Q1 2025 10-Q filed. Financials and ops update.

AI Summary

IMMUNIC, INC. filed its quarterly report for the period ending March 31, 2025. The company, formerly known as VITAL THERAPIES INC, is based in New York and operates in the pharmaceutical preparations sector. Key financial data and operational details for the first quarter of 2025 are presented in this filing.

Why It Matters

This filing provides investors and analysts with the latest financial performance and operational updates for IMMUNIC, INC. during the first quarter of 2025.

Risk Assessment

Risk Level: low — This is a standard quarterly filing providing financial and operational updates, not indicating immediate high risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of IMMUNIC, INC.?

IMMUNIC, INC. operates in the Pharmaceutical Preparations sector, as indicated by its Standard Industrial Classification code [2834].

When was the company formerly known as VITAL THERAPIES INC?

The company changed its name from VITAL THERAPIES INC on February 19, 2004.

What is the fiscal year end for IMMUNIC, INC.?

The fiscal year end for IMMUNIC, INC. is December 31.

Where is IMMUNIC, INC. located?

IMMUNIC, INC. is located at 1200 Avenue of the Americas, Suite 200, New York, NY 10036.

What period does this 10-Q filing cover?

This 10-Q filing covers the period ending March 31, 2025.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding IMMUNIC, INC. (IMUX).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing